查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401931

2030 年乾粉吸入器市場預測：按產品、功能、適應症、最終用戶和地區進行的全球分析

Dry Powder Inhalers Market Forecasts to 2030 - Global Analysis By Product (Multi Dose Dry Powder Inhalers and Single Dose Dry Powder Inhalers), Function, Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球乾粉吸入器市場規模為 214.8 億美元，預計預測期內複合年成長率為 6.6%，到 ​​2030 年將達到 336 億美元。

乾粉吸入器是一種將粉末狀藥物直接吸入肺部的醫療設備。它經常被用來治療肺部相關和呼吸系統疾病，例如氣喘和慢性阻塞性肺病（COPD）。與定量噴霧吸入器(MDI) 相比，它們不需要推進劑來輸送藥物，也不需要手部呼吸協調，這使得它們適合那些難以使用 MDI 的人。

根據2020年4月發表的一篇題為《常見呼吸系統疾病》的論文，約15%的老年人患有氣喘、慢性阻塞性肺病或其他呼吸系統疾病。

呼吸道疾病盛行率上升

囊腫纖維化、氣喘和慢性阻塞性肺病(COPD) 等呼吸系統疾病的盛行率不斷增加，直接推動了對有效吸入療法的需求。乾粉吸入器作為治療這些疾病的一種手段有著很高的需求，因為它們提供了一種將藥物直接輸送到肺部的實用且有效的方法。隨著患有呼吸道疾病的人數不斷增加，越來越重視症狀管理、避免病情加重和加強整體疾病控制對於維持長期症狀控制和即時緩解症狀非常重要。乾粉吸入器擴大被使用，發揮著關鍵作用。對市場成長的推動作用。

製造成本高、應用困難

由於疾病管理困難而導致的藥物不依從性可能會導致治療不足、疾病惡化和醫療費用增加。如果患者發現難以操作或裝載乾粉吸入器，他們可以選擇使用替代吸入器，例如霧化器或定量吸入器（MDI）。這些偏好的變化可能會影響乾粉吸入器的市場佔有率和銷售。醫療保健提供者可能需要投入額外的時間和資源來教導患者正確的處理和裝載技術。這種額外的培訓需求可能會增加病患教育計畫的複雜性，進而可能增加醫療成本並阻礙市場成長。

日益關注預防醫學和疾病管理

隨著醫療保健系統和提供者越來越關注預防性護理，我們鼓勵他們關注早期療育策略。我們透過提供預防性藥物治療來控制症狀和阻止病情惡化，為呼吸系統疾病的治療做出了重大貢獻。隨著重點轉向疾病預防和管理，以病人為中心的照護模式變得越來越重要。乾粉吸入器是這些護理模式的補充，使患者能夠主動管理呼吸系統疾病，因為它們易於使用且適合自我給藥。

由於競爭激烈，原料的可得性

對乾粉吸入器等藥物治療方案的依從性差可能導致慢性阻塞性肺病和氣喘等呼吸系統疾病的治療不充分。肺功能下降、病情加重頻率增加、症狀惡化、住院風險增加都可能是由於給藥不完整或不規則造成的。此外，如果患者因各種原因（例如吸入困難）不遵守規定，患者的偏好要求和處方率都會受到影響。因此，它的市場佔有率可能比其他類型的吸入器要小。

COVID-19 的影響

疫情期間，隨著 COVID-19 提高了人們對呼吸系統健康的認知和對肺部健康的擔憂，對包括 DPI 在內的呼吸系統藥物的需求激增。患有長期呼吸道疾病的患者尋求獲得所需的藥物並繼續他們的治療計劃。由於行動不便和前往醫療機構就診的限制，出現了在家中自行用藥的趨勢。 DPI 可以自我給藥且易於使用，使其成為治療難以定期去醫院就診的呼吸系統疾病的理想選擇。

高劑量乾粉吸入器細分市場預計將在預測期內成為最大的細分市場

多劑量乾粉吸入器領域預計將出現良好的成長，因為它用於將粉狀藥物直接給藥肺部。他們通常使用一個儲存器來容納多劑量的粉末藥物，允許患者隨著時間的推移服用多次劑量。該設備可以預先安裝多種給藥，為患者給藥彈性，並允許他們按照預定的時間間隔服用建議的劑量。為了滿足患者需求並改善治療效果，該細分市場的製造商不斷創新並專注於改進給藥系統、設備人體工學和給藥精度。

數位吸入器設備預計在預測期內複合年成長率最高。

預計數位操作吸入器設備領域在預測期內將出現最高的複合年成長率。這些吸入器中的數位技術可以改善資料追蹤、連接性和患者更好地醫囑遵從性處方時間表等功能。因此，在吸入器設備中添加數位組件的目的是增強對慢性阻塞性肺病（COPD）和氣喘等呼吸系統疾病的治療。數位化操作的吸入器可以支援個人化醫療方法，因為它們可以收集個別患者對治療的反應和吸入器使用模式的資料，從而推動市場成長。

佔有率最大的地區

由於旨在加強呼吸系統健康和疾病管理的眾多政府計劃和醫療保健法規，預計亞太地區將在預測期內佔據最大的市場佔有率。支持政策經常鼓勵採用 DPI 和其他有效的吸入療法。透過 DPI 和數位技術（例如提供給藥追蹤、提醒和連接等功能的智慧吸入器）的結合，可以改善患者的醫囑遵從性和管理。這種以患者為中心的方法正在推動市場的發展。

複合年成長率最高的地區：

氣喘和慢性阻塞性肺病等呼吸系統疾病的盛行率不斷增加，增加了對有效吸入治療的需求。 DPI 為治療這些疾病提供了一種實用且有效的藥物給藥方式。此外，由於藥物輸送系統、配方和 DPI 設計的不斷創新，市場正在不斷成長。為了提高藥物醫囑遵從性和有效性，製造商不斷致力於開發可攜式、易於使用且高效的 DPI。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球乾粉吸入器市場：依產品

  • 多劑量乾粉吸入器
  • 單給藥乾粉吸入器

第6章全球乾粉吸入器市場：依功能分類

  • 手動吸入器
  • 數位操作吸入器

第7章全球乾粉吸入器市場：依適應症分類

  • 肺動脈高血壓
  • 慢性阻塞性肺病（COPD）
  • 氣喘
  • 囊腫纖維化

第8章全球乾粉吸入器市場：依最終用戶分類

  • 藥局
  • 零售藥房
  • 醫院
  • 線上藥房
  • 門診手術中心
  • 其他最終用戶

第9章全球乾粉吸入器市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • GlaxoSmithKline Plc
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • Chiesi Farmaceutici SpA
  • AptarGroup, Inc.
  • Iconovo AB
  • Mylan NV
  • Pharmaxis
  • Teva Pharmaceutical Industries Limited
  • AstraZeneca Plc
  • Novartis AG
  • Elpen SA
  • Vectura Group Plc
  • Beximco Pharmaceuticals Ltd
  • Hovione
  • MannKind Corporation
  • Sava Healthcare Ltd
  • 3M Company
  • DPI Co., Ltd.
Product Code: SMRC24451

According to Stratistics MRC, the Global Dry Powder Inhalers Market is accounted for $21.48 billion in 2023 and is expected to reach $33.60 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dry powder inhalers are medical devices that inhale powdered medication directly into the lungs. For the treatment of lung-related disorders and respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), they are frequently prescribed. They don't need propellants to deliver the medication, in contrast to metered-dose inhalers (MDIs) and are also appropriate for people who might have trouble using MDIs because they do not require hand-breath coordination.

According to the article titled "Common Respiratory Disorders" published in April 2020 around 15% of older adults from asthma, chronic obstructive pulmonary disease, or another respiratory disorder.

Market Dynamics:

Driver:

Rising prevalence of respiratory disorders

The increasing prevalence of respiratory ailments such as cystic fibrosis, bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) directly drives the need for efficient inhalation therapies. Since dry powder inhalers provide a practical and effective means of delivering medication directly to the lungs, they are in high demand as a treatment modality for these conditions. The increasing number of people suffering from respiratory disorders has led to a greater focus on symptom management, averting exacerbations, and enhancing overall disease management and these are used more frequently because of their critical role in sustaining long-term symptom control and offering immediate relief which drives the growth of the market.

Restraint:

High production costs and difficulty in application

Medication noncompliance brought on by difficulties managing the condition may lead to insufficient therapy, worsening of the illness, and higher medical expenses. If patients find Dry powder inhalers difficult to handle or load, they may choose to use alternative inhaler devices like nebulizers or metered-dose inhalers (MDIs). The market share and sales of dry powder inhalers may be impacted by this change in preferences. It may be necessary for healthcare providers to devote additional time and resources to instructing patients on proper handling and loading techniques. The complexity of patient education programs may increase due to this additional training requirement, which may also raise healthcare costs thus hamper the growth of the market.

Opportunity:

Increased focus on preventive care and disease management

Healthcare systems and providers are encouraged to concentrate on early intervention strategies due to the increased emphasis on preventive care. By offering prophylactic medication to manage symptoms and stop exacerbations and they contribute significantly to the management of respiratory conditions. Patient-centric care models are becoming more and more important as the focus shifts to illness prevention and management. Dry powder inhalers complement these care models by empowering patients to actively manage their respiratory conditions because they are easy to use and appropriate for self-administration.

Threat:

Availability of raw materials with intense competition

Insufficient compliance with drug regimens, such as dry powder inhalers, may result in insufficient treatment of respiratory disorders like COPD or asthma. Reduced lung function, an increase in the frequency of exacerbations, worsening symptoms, and an increased risk of hospitalization can all be caused by incomplete or irregular dosing. Moreover, demand of patient preferences, and prescription rates may all be impacted if patients fail to comply for a variety of reasons, such as inhaler difficulties. This might result in having a smaller market share than other kinds of inhalers.

COVID-19 Impact

Demand for respiratory medications, including those given through DPIs, surged during the pandemic as a result of increased awareness of respiratory health and worries about lung health brought on by COVID-19. Patients with long-term respiratory disorders tried to get access to the drugs they needed and continue their treatment plans. There was a move toward at-home medication self-administration due to limitations on mobility and visits to medical facilities. Due to their self-administration capabilities and ease of use, DPIs have become the go-to choice for treating respiratory disorders when regular clinic visits are not feasible.

The multi dose dry powder inhalers segment is expected to be the largest during the forecast period

The multi dose dry powder inhalers segment is estimated to have a lucrative growth, as they are used to administer powdered medication directly into the lungs. They usually use a reservoir that holds multiple doses of the powdered medication, allowing patients to take multiple doses over time. They enable the device to be preloaded with multiple doses, giving patients dosage flexibility and the ability to take their recommended doses at predetermined intervals. In order to meet patient needs and enhance treatment outcomes, manufacturers in this market sector are constantly innovating, concentrating on bettering drug delivery systems, ergonomics of devices, and dose accuracy.

The digitally operated inhaler devices segment is expected to have the highest CAGR during the forecast period

The digitally operated inhaler devices segment is anticipated to witness the highest CAGR growth during the forecast period, because digitally operated inhaler devices are a new and creative segment. Digital technology in these inhalers enables improved features like data tracking, connectivity, and better patient adherence to prescription schedules. Thus, the goal of adding digital components to inhaler devices is to enhance the way respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are managed. Because digitally operated inhalers collect data on individual patient responses to treatment and inhaler usage patterns, they can support personalized medicine approaches thus boosting the growth of the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the as a result of numerous government programs and healthcare regulations targeted at enhancing respiratory health and illness management. Adoption of DPIs and other effective inhalation therapies is frequently encouraged by supportive policies. Patient adherence and management are improved by the combination of DPIs with digital technologies, such as smart inhalers that provide features like dose tracking, reminders, and connectivity. The evolution of the market is driven by this patient-centric approach.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the incidence of respiratory conditions such as asthma and COPD has been increasing, which has increased the need for efficient inhalation treatments. DPIs provide a practical and effective means of administering medicine to treat these ailments. Moreover, the market has grown as a result of ongoing innovations in drug delivery systems, formulations, and DPI designs. To increase medication adherence and efficacy, manufacturers are always working to create DPIs that are more portable, user-friendly, and efficient.

Key players in the market:

Some of the key players profiled in the Dry Powder Inhalers Market include GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A, AptarGroup, Inc., Iconovo AB, Mylan N.V, Pharmaxis, Teva Pharmaceutical Industries Limited, AstraZeneca Plc, Novartis AG, Elpen S.A, Vectura Group Plc, Beximco Pharmaceuticals Ltd, Hovione, MannKind Corporation, Sava Healthcare Ltd, 3M Company and DPI Co., Ltd.

Key Developments:

In October 2023, GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen. There is high unmet need in CHB with an estimated 300 million people living with the disease and a less than 3-7% functional cure rate with current treatment options.

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. New research reveals a nationwide focus on STEM mentoring of under-represented groups could boost individual incomes.

In October 2023, Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs

Products Covered:

  • Multi Dose Dry Powder Inhalers
  • Single Dose Dry Powder Inhalers

Functions Covered:

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

Indications Covered:

  • Pulmonary Arterial Hypertension
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Cystic Fibrosis

End Users Covered:

  • Drug Stores
  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dry Powder Inhalers Market, By Product

  • 5.1 Introduction
  • 5.2 Multi Dose Dry Powder Inhalers
  • 5.3 Single Dose Dry Powder Inhalers

6 Global Dry Powder Inhalers Market, By Function

  • 6.1 Introduction
  • 6.2 Manually Operated Inhaler Devices
  • 6.3 Digitally Operated Inhaler Devices

7 Global Dry Powder Inhalers Market, By Indication

  • 7.1 Introduction
  • 7.2 Pulmonary Arterial Hypertension
  • 7.3 Chronic Obstructive Pulmonary Disease (COPD)
  • 7.4 Asthma
  • 7.5 Cystic Fibrosis

8 Global Dry Powder Inhalers Market, By End User

  • 8.1 Introduction
  • 8.2 Drug Stores
  • 8.3 Retail Pharmacies
  • 8.4 Hospitals
  • 8.5 Online Pharmacies
  • 8.6 Ambulatory Surgical Centers
  • 8.7 Other End Users

9 Global Dry Powder Inhalers Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GlaxoSmithKline Plc
  • 11.2 Boehringer Ingelheim GmbH
  • 11.3 Cipla Limited
  • 11.4 Chiesi Farmaceutici S.p.A
  • 11.5 AptarGroup, Inc.
  • 11.6 Iconovo AB
  • 11.7 Mylan N.V
  • 11.8 Pharmaxis
  • 11.9 Teva Pharmaceutical Industries Limited
  • 11.10 AstraZeneca Plc
  • 11.11 Novartis AG
  • 11.12 Elpen S.A
  • 11.13 Vectura Group Plc
  • 11.14 Beximco Pharmaceuticals Ltd
  • 11.15 Hovione
  • 11.16 MannKind Corporation
  • 11.17 Sava Healthcare Ltd
  • 11.18 3M Company
  • 11.19 DPI Co., Ltd.

List of Tables

  • Table 1 Global Dry Powder Inhalers Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 4 Global Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 5 Global Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 6 Global Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 7 Global Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 8 Global Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 9 Global Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 10 Global Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 11 Global Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 12 Global Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 13 Global Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 14 Global Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 15 Global Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 17 Global Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 18 Global Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 19 Global Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 23 North America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 24 North America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 25 North America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 26 North America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 27 North America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 28 North America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 29 North America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 30 North America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 31 North America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 32 North America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 North America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 34 North America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 35 North America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 36 North America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 North America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 38 North America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 42 Europe Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 43 Europe Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 44 Europe Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 45 Europe Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 46 Europe Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 47 Europe Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 48 Europe Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 49 Europe Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 50 Europe Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 51 Europe Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 52 Europe Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 53 Europe Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 54 Europe Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 55 Europe Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 57 Europe Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 61 Asia Pacific Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 62 Asia Pacific Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 63 Asia Pacific Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 64 Asia Pacific Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 65 Asia Pacific Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 66 Asia Pacific Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 67 Asia Pacific Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 68 Asia Pacific Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 69 Asia Pacific Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 70 Asia Pacific Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 71 Asia Pacific Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 72 Asia Pacific Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 73 Asia Pacific Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 74 Asia Pacific Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 76 Asia Pacific Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 80 South America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 81 South America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 82 South America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 83 South America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 84 South America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 85 South America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 86 South America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 87 South America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 88 South America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 89 South America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 South America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 91 South America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 92 South America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 93 South America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 94 South America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 95 South America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 99 Middle East & Africa Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 100 Middle East & Africa Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 101 Middle East & Africa Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 102 Middle East & Africa Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 103 Middle East & Africa Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 104 Middle East & Africa Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 105 Middle East & Africa Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 106 Middle East & Africa Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 107 Middle East & Africa Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 108 Middle East & Africa Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 109 Middle East & Africa Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 110 Middle East & Africa Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 111 Middle East & Africa Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 112 Middle East & Africa Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 114 Middle East & Africa Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)